eligible men or women were age over 14，but less than 60 years;

eastern cooperative oncology group performance status of 0 to2;

diagnosed with all (who classification, the primitive cells ≥ 20%);

previous untreated all patients had not received chemotherapy before (excluding dexamethasone, prednisone, and hydroxyurea). history of receiving blood transfusion, hematopoietic growth factors, vitamin, and palliative measures such as leukocyte removal, dexamethasone, prednisone, hydroxyurea (0.5-3g daily, more than three days) is allowed;

the levels of lscs in bone marrow were measured with flow cytometry before treatment;

subjects must be able to provide written informed consent.

mixed type of all patients;

clinically significant active infections;

nursing (breastfeeding) or intending to be nursing during the study；

pregnancy, or intending to become pregnant during the study;

patients with cardiac dysfunction currently (especially congestive heart failure) or history of congestive heart failure;

patients with severe liver failure (alt ≥ 5 times the upper limit of normal (uln), total bilirubin ≥ 3mg/dl)

patients with renal insufficiency, creatinine clearance <30ml/min, creatinine clearance rate is calculated as follows: men: ccr (ml / min) = (140 - age) × weight (kg) / [0.8136 ×serum creatinine (μmol / l )] female: ccr (ml / min) = (140 - age) × weight (kg) × 0.85 /[0.8136 × serum creatinine (μmol / l)];

patients did not or will not participate in other trials of drugs 30 days before or 90 days after the beginning of this study,